Biotech Investors & VC Firms in Luxembourg
14 firms in this list, with a median first check of $545K. 5 of them lead rounds. Generated from verified public data and updated continuously.
Droia Ventures
LuxembourgSeed–Series B$540K
40 people
Balnord Sp. z o.o.
LuxembourgPre-Seed–Seed$550K – $3.3M
14 people
Expon Capital
LuxembourgSeed–Growth$550K – $1.6M
5 people
Vesna Advisors
LuxembourgPre-Seed–Series A$200K – $700K
6 people
i&i Biotech Fund
LuxembourgPre-Seed–Series A$150K – $2M
9 people
Neulogy Ventures
LuxembourgSeed–Series A$216K – $3.2M
5 people
Maia Ventures
LuxembourgPre-Seed–Series A$550K – $1.6M
8 people
Neurone Group
LuxembourgSeed–Late Stage
11 people
Vesalius Biocapital Partners
LuxembourgSeed–Growth$11M
5 people
Beyond Impact
Luxembourg
2 people
EQT Life Sciences
AmsterdamSeed–Late Stage$11M – $66M
59 people
Bootstrap Europe
LondonGrowth–Late Stage
23 people
Systemiq Capital
LondonSeries A
16 people
Genii Capital
HowaldGrowth–Late Stage
Frequently asked questions
- Who are the top biotech investors & vc firms in luxembourg?
- Top biotech investors & vc firms in luxembourg include Droia Ventures, Balnord Sp. z o.o., Expon Capital, Vesna Advisors, i&i Biotech Fund, Neulogy Ventures, Maia Ventures, Neurone Group — 14 firms in total meet the criteria.
- What is the typical first check among biotech investors & vc firms in luxembourg?
- The median first check among the 14 biotech investors & vc firms in luxembourg tracked here is $545K.
- How many biotech investors & vc firms in luxembourg lead rounds?
- 5 of the 14 biotech investors & vc firms in luxembourg tracked here lead investment rounds.
Related lists
Investors & VC Firms in North America (12929)Investors & VC Firms in United States (11967)Investors & VC Firms in Europe (5859)Investors & VC Firms in Global (4787)AI & Machine Learning Investors & VC Firms (4629)Fintech Investors & VC Firms (4588)SaaS Investors & VC Firms (4239)Healthtech Investors & VC Firms (4227)Enterprise Software Investors & VC Firms (4136)Crypto & Web3 Investors & VC Firms (3986)
Data sourced from public filings and firms' own websites — see our methodology.






















































